SXTPW

distress 6/10 · elevated risk

$0.04+28%today-16% from 52w high

Lead: chronic babesiosis

Revenue

pre-revenue

Liquidity

$5M

Runway

0.6 yrs

Shares 1y

-35%

Price & events

-16.3% over 6M

CatalystRating changeDilutionFinancingdashed = today

+27.5%

+0.0%

—

-16.3%

All

Overview

Market Cap: $101.05K
Enterprise Value: $-3.09M
Volume: 0
52 Week Range: $0.03 – $0.05
Total Shares: 2.66M

Pipeline · 0 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
No pipeline trials tracked.

Catalyst news & presentations · 2

Q3 2025trial initiationsecondaryPhase 2tafenoquine · Enrollment expected to commence Q3 2025 for Phase II study of tafenoquine in chronic babesiosis.SEC 8-K
January 8, 2025trial initiationsecondarytafenoquine · First patient enrolled in expanded access clinical study NCT06478641.SEC 8-K

Approved drugs (1)

ARAKODATAFENOQUINE SUCCINATE2018 · Prescription

Capital structure — dilution & financing

Shares out: 2,659,288 · 4 offerings/1y · 0 PIPEs

2026-03-13424B5offering
2026-03-11424B5offering
2026-03-02424B5offering
2025-09-058-Kmaterial_agreement
2025-09-05424B5offering
2025-07-188-Kmaterial_agreement
2025-07-16424B4offering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

no recent rating changes

Competitors — chronic babesiosis

SXTP60 DEGREES PHARMACEUTICALS, INC.$4M · D5